Cucurbitacin: As a candidate against Cytokine Storm in Severe COVID-19 Infection

Alka Hande*, Akhilesh Agrawal, Archanaa Sonone, Amol Gadbail, Madhuri Gawande, Swati Patil
Department of Oral Pathology & Microbiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha-442001, Maharashtra, India

Article History:
Received on: 21 Jul 2020
Revised on: 21 Aug 2020
Accepted on: 27 Aug 2020

Keywords:
SARS-CoV-2, Cytokine Storm, Cucurbitacins

ABSTRACT
The severity of SARS-CoV-2 infection is marked by elevated cytokines and chemokines levels like interleukin 6 (IL-6), interferon-gamma (IFN-γ), tumour necrosis factor (TNF), IL-2 and monocyte chemotactic protein 1. This hyperactive pro-inflammatory response identified as the Cytokine Storm (CS) complicates the disease leading to extensive damage of the host tissue, Acute Respiratory Distress Syndrome (ARDS), which further result in multiple organ failures. CS is very critical for the disease progression and is responsible for high death rate in an infected patient. Accordingly, various therapeutic modalities are currently investigated for their effectiveness in subsiding the hyper-inflammatory syndrome either using immunomodulatory agents or anti-inflammatory therapies. Phytochemical (herbal) compounds are demonstrated to possess anti-inflammatory, antimicrobial or antioxidants properties. Various signalling pathways and molecules exacerbating the inflammation state complicate the pathophysiology of COVID-19. Cucurbitacins are tetracyclic bioactive phytochemical compounds found in cucurbitaceous plants. More than 100 species of cucurbitacins possess various pharmacological properties, including anti-inflammatory. Cucurbitacin E and R have shown to be down-regulated the expression of TNF alpha and IL-1beta. Cucurbitacin II B also alleviates the expression of TNF-α as well as IFN-γ and IL-6. Cucurbitacin1 has the potential to reduce the oxidative stress-induced with the reactive oxygen species, and thus prevents cardiovascular damage. Thus cucurbitacins may be pharmacologically manipulated to establish its clinical efficacy in minimizing the disease state and improving the prognosis of the patients.

INTRODUCTION
The COVID-19 pandemic commenced across the globe due to the spread of positive-sense ssRNA novel coronavirus 2019 (also known as SARS-CoV-2). The disease severity is marked by elevated cytokines and chemokines levels like interleukin 6 (IL-6), interferon-gamma (IFN-γ), tumour necrosis factor (TNF), IL-2 and monocyte chemotactic protein 1 etc. Such hyperactive pro-inflammatory response is identified as the Cytokine Storm (CS) that complicates the disease leading to extensive damage of the host tissue, Acute Respiratory Distress Syndrome (ARDS) and may result in mul-
Cucurbitacins may explore the antiviral properties of SARS-CoV-2 binding to toll-like receptors up-regulates IL-1 beta by formation and activation of pro-IL-1 and inflammasome respectively. Hyper-secretion of IL-1beta aggravates the inflammation in the lung inducing fibrosis in the pulmonary tissue (Conti et al., 2020). In an in-vitro study cucurbitacin E down-regulated the expression of TNF alpha and IL-1beta by repressing the nuclear factor-kappa B (NF-κB) translocation. This inhibition of pro-inflammatory cytokines may be due to disruption in the actin cytoskeleton of the cells inhibiting NF-κB translocation (Qiao et al., 2013). In a rat model of adjunct arthritis, cucurbitacin R also suppressed TNF alpha and IL-1beta via suppression of the signal transducer and activator of transcription 3 (STAT3) signalling (Escandell et al., 2007).

Further, Cucurbitacin II B not only suppressed NF-κB translocation but also prevented phosphorylation of extracellular-signal-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK), alleviating the expression of inflammatory cytokines like TNF-α, IFN-γ and IL-6 (Wang et al., 2014). Cucurbitacin 1 has the potential to reduce the oxidative stress-induced with the reactive oxygen species (ROS) in H9c2 cardiomyoblasts (Yang and Kim, 2018). Thus, cucurbitacins may prevent cardiovascular damage associated with COVID-19 disease.

Various signalling pathways and molecules exacerbating the inflammation state complicate the pathophysiology of COVID-19. Cucurbitacins may be pharmacologically manipulated to establish its clinical efficacy in minimizing the disease state and improvising the prognosis of the patients. However, the effect of these compounds on the human body and its metabolism needs further investigations. Besides, research experts in phytochemical compounds may explore the antiviral properties of cucurbitacins.

CONCLUSIONS

The interleukin 6 (IL-6), interferon-gamma (IFN-γ), tumour necrosis factor (TNF), IL-2 and monocyte chemotactic protein 1 are few of the cytokines and chemokines, known to be elevated in SARS-CoV-2 infection. Various therapeutic modalities using phytochemical compounds are currently investigated for their effectiveness in subsiding the hyper-inflammatory syndrome. Cucurbitacin E and R have shown to be down-regulated the expression of TNF alpha and IL-1beta. Cucurbitacin II B also alleviates the expression of TNF-α as well as IFN-γ and IL-6. Cucurbitacin1 has the potential to reduce the oxidative stress-induced with the reactive oxygen species, and thus prevents cardiovascular damage. Thus cucurbitacins may be pharmacologically manipulated to establish its clinical efficacy in minimizing the disease state and improvising the prognosis of the patients.

Conflict of interest

The authors declare that they have no conflict of interest for this study.

Funding support

The authors declare that they have no funding support for this study.

REFERENCES

Aeri, V., Kaushik, U., Mir, S. 2015. Cucurbitacins - An insight into medicinal leads from nature. Pharmacognosy Reviews, 9(17):12–12.
Conti, P., Ronconi, G., Caraffa, A., Gallenga, C., Ross, R., Frydas, I. 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents, 14(2).
Escandell, J. M., Recio, M. C., Máñez, S., Giner, R. M., Cerdá-Nicolás, M., Rios, J. L. 2007. Cucurbitacin R Reduces the Inflammation and Bone Damage Associated with Adjuvant Arthritis in Lewis Rats by Suppression of Tumor Necrosis Factor-α in T Lymphocytes and Macrophages. Journal of Pharmacology and Experimental Therapeutics, 320(2):581–590.
Qiao, J., hui Xu, L., He, J., yun Ouyang, D., hui He, X. 2013. Cucurbitacin E exhibits anti-inflammatory effect in RAW 264.7 cells via suppression of NF-κB nuclear translocation. Inflammation Research, 62(5):461–469.
Wang, Y., Zhao, G. X., Xu, L. H., Liu, K. P., Pan, H., He, J., Cai, J. Y., Ouyang, D. Y., He, X. H. 2014. Cucurbitacin IIb Exhibits Anti-Inflammatory Activity through...
Modulating Multiple Cellular Behaviors of Mouse Lymphocytes. *PLoS ONE, 9*(2).

Yang, D. K., Kim, S. J. 2018. Cucurbitacin I Protects H9c2 Cardiomyoblasts against H2O2-Induced Oxidative Stress via Protection of Mitochondrial Dysfunction. *Oxidative Medicine and Cellular Longevity*, pages 1–11.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., Cao, B. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*, 395:30566–30569.